All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Ivosidenib in combination with azacitidine receives FDA approval for the treatment of IDH1-mutated newly diagnosed AML

May 31, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

On May 25, 2022, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of ivosidenib tablets in combination with azacitidine for IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Ivosidenib is a small molecular IDH1 inhibitor, already approved across multiple IDH1-mutated cancer types. This expanded approval follows results from the phase III AGILE trial (NCT03173248), previously summarized in a visual abstract on the AML Hub, in which ivosidenib plus azacitidine demonstrated significantly improved event-free survival, overall survival, and overall response rate compared with azacitidine plus placebo. The safety profile was favorable in both treatment arms, and the most common adverse events were febrile neutropenia, anemia, thrombocytopenia, and pneumonia (22.5%).

  1. Servier. Servier announces FDA approval of TIBSOVO® (ivosidenib tablets) in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia. https://www.servier.us/fda-approval-tibsovo-aml. Published May 25, 2022. Accessed May 31, 2022.

Share: